BioSpace News Archive

- Company to host Conference Call Today at 4:30 p.m. ET -

Apyx Medical Corporation, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, reported financial results for its first quarter ended March 31, 2020.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced that the Company will present at and/or participate in the following virtual investor conferences in May and June: - RBC 2020 Capital Markets Global Healthcare Conference on May 19-20, 2020 - SVB Leerink CybeRx Series: Digital Health - Innovators & Disruptors on May 21, 2020 - Jef

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be presenting at the Bank of America Securities Health Care Conference 2020 on Thursday, May 14, 2020 via webcast.

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported operating results for the first quarter ended March 31, 2020.

Patients treated with LYNPARZA and bevacizumab lived without disease progression for 37.2 months vs. 17.7 months median for bevacizumab alone

Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH, both subsidiaries of Hitachi Chemical Co., Ltd. announced that they have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including:.

Collaboration focuses on gene therapies for serious eye diseases and leverages Dyno’s CapsidMap™ artificial intelligence platform to design AAV vectors

DexCom, Inc. announced that it intends to offer, subject to market conditions and other factors, $850.0 million aggregate principal amount of Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

AtriCure, Inc. announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares of its common stock pursuant to its existing automatic shelf registration statement.